Adriana C Vidal1, Stephen J Freedland2. 1. Department of Surgery, Cedars-Sinai Medical Center and Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA. Electronic address: adriana.vidal@cshs.org. 2. Department of Surgery, Cedars-Sinai Medical Center and Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.
Abstract
CONTEXT: In 2012, we published a detailed review on obesity and prostate cancer. Since then, new studies have brought further understanding regarding the role of obesity in selecting active surveillance candidates, and differing associations between obesity and prostate cancer as a function of race and molecular subtype of prostate cancer. OBJECTIVE: To review new manuscripts on these new concepts for which there were limited data before 2012. EVIDENCE ACQUISITION: A PubMed search from July 2012 to March 2016 was performed using the terms "prostate cancer" and "obesity". Of 450 articles, we included 15 related to these three topics. EVIDENCE SYNTHESIS: Among men on active surveillance or candidates for active surveillance, multiple studies suggest that the risk of upgrading is higher for obese men. No study has shown long-term oncologic differences, and the risk of prostate cancer mortality remains low. One study suggested that the link between obesity and prostate cancer risk is stronger among black men; however, other studies found that obesity is correlated with aggressive disease regardless of race. Two studies found that the associations between obesity and prostate cancer (ie, fewer low-grade cancers and yet more aggressive cancers) was limited to men with TMPRSS2-ERG-positive tumors. CONCLUSIONS: The past 4 yr has seen much new work on the obesity-prostate cancer link. If confirmed in other studies, these findings provide novel insights into not only the link between obesity and prostate cancer but also prostate cancer biology in general. PATIENT SUMMARY: While their outcomes may be slightly worse, obese men with localized prostate cancer should not be discouraged from active surveillance. Early studies suggest there may be subtypes of patients in whom obesity is more strongly linked to aggressive disease.
CONTEXT: In 2012, we published a detailed review on obesity and prostate cancer. Since then, new studies have brought further understanding regarding the role of obesity in selecting active surveillance candidates, and differing associations between obesity and prostate cancer as a function of race and molecular subtype of prostate cancer. OBJECTIVE: To review new manuscripts on these new concepts for which there were limited data before 2012. EVIDENCE ACQUISITION: A PubMed search from July 2012 to March 2016 was performed using the terms "prostate cancer" and "obesity". Of 450 articles, we included 15 related to these three topics. EVIDENCE SYNTHESIS: Among men on active surveillance or candidates for active surveillance, multiple studies suggest that the risk of upgrading is higher for obesemen. No study has shown long-term oncologic differences, and the risk of prostate cancer mortality remains low. One study suggested that the link between obesity and prostate cancer risk is stronger among black men; however, other studies found that obesity is correlated with aggressive disease regardless of race. Two studies found that the associations between obesity and prostate cancer (ie, fewer low-grade cancers and yet more aggressive cancers) was limited to men with TMPRSS2-ERG-positive tumors. CONCLUSIONS: The past 4 yr has seen much new work on the obesity-prostate cancer link. If confirmed in other studies, these findings provide novel insights into not only the link between obesity and prostate cancer but also prostate cancer biology in general. PATIENT SUMMARY: While their outcomes may be slightly worse, obesemen with localized prostate cancer should not be discouraged from active surveillance. Early studies suggest there may be subtypes of patients in whom obesity is more strongly linked to aggressive disease.
Authors: Lieke Egbers; Manuel Luedeke; Antje Rinckleb; Suzanne Kolb; Jonathan L Wright; Christiane Maier; Marian L Neuhouser; Janet L Stanford Journal: Am J Epidemiol Date: 2015-04-07 Impact factor: 4.897
Authors: Wendy E Barrington; Jeannette M Schenk; Ruth Etzioni; Kathryn B Arnold; Marian L Neuhouser; Ian M Thompson; M Scott Lucia; Alan R Kristal Journal: JAMA Oncol Date: 2015-06 Impact factor: 31.777
Authors: Matthew Truong; Jon A Slezak; Chee Paul Lin; Viacheslav Iremashvili; Martins Sado; Aria A Razmaria; Glen Leverson; Mark S Soloway; Scott E Eggener; E Jason Abel; Tracy M Downs; David F Jarrard Journal: Cancer Date: 2013-09-04 Impact factor: 6.860
Authors: R B Hayes; R G Ziegler; G Gridley; C Swanson; R S Greenberg; G M Swanson; J B Schoenberg; D T Silverman; L M Brown; L M Pottern; J Liff; A G Schwartz; J F Fraumeni; R N Hoover Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-01 Impact factor: 4.254
Authors: Tammy Ho; Leah Gerber; William J Aronson; Martha K Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Eur Urol Date: 2012-08-20 Impact factor: 20.096
Authors: Emma H Allott; Lauren E Howard; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Stephen J Freedland Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-01-25 Impact factor: 4.254
Authors: Onisuru T Okotie; William J Aronson; Jeff A Wieder; Yen Liao; Fred Dorey; Jean B DeKERNION; Stephen J Freedland Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: B Gumuskaya; B Gurel; H Fedor; H-L Tan; C A Weier; J L Hicks; M C Haffner; T L Lotan; A M De Marzo Journal: Prostate Cancer Prostatic Dis Date: 2013-04-02 Impact factor: 5.554
Authors: Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Christopher J Kane; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2018-04-10 Impact factor: 5.588
Authors: Justin R Gregg; Jiali Zheng; David S Lopez; Chad Reichard; Gladys Browman; Brian Chapin; Jeri Kim; John Davis; Carrie R Daniel Journal: Br J Cancer Date: 2019-01-25 Impact factor: 7.640